Alembic Pharmaceuticals Limited (BOM:533573)
India · Delayed Price · Currency is INR | Market Cap | 144.69B -18.3% |
| Revenue (ttm) | 73.45B +10.1% |
| Net Income | 6.75B +15.7% |
| EPS | 34.33 +15.7% |
| Shares Out | n/a |
| PE Ratio | 21.44 |
| Forward PE | 19.50 |
| Dividend | 11.00 (1.45%) |
| Ex-Dividend Date | Jul 29, 2025 |
| Volume | 10,806 |
| Open | 765.40 |
| Previous Close | 754.60 |
| Day's Range | 725.50 - 765.40 |
| 52-Week Range | 635.30 - 1,107.80 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 907.20 (+23.41%) |
| Earnings Date | May 15, 2026 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspe... [Read more]
Financial Performance
In fiscal year 2026, Alembic Pharmaceuticals's revenue was 73.45 billion, an increase of 10.08% compared to the previous year's 66.72 billion. Earnings were 6.75 billion, an increase of 15.66%.
Financial StatementsNews
Alembic Pharmaceuticals gets USFDA nod for thyroid treatment tablets
Alembic Pharmaceuticals Ltd on Friday announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sod...
Pharma sector stocks today, May 22: Aurobindo Pharma falls 4.11%, Zydus Lifesciences rises 0.92%, Alembic Pharma up 1.06%
Pharmaceutical stocks traded mixed on May 22, 2026, during the morning session. While some stocks posted modest gains, a few names, including Aurobindo Pharma, witnessed sharp declines. The BSE Health...
Alembic Pharmaceuticals shares fall 8% on May 18 as Q4FY26 PAT misses estimates by 43% and Motilal Oswal cuts FY27 earnings by 12%
Shares of Alembic Pharmaceuticals Limited fell 8.02% to ₹721.25 on the NSE on May 18, 2026, shedding ₹62.85 from a previous close of ₹784.10, after the company's Q4FY26 results missed…
Pharma sector stocks fall today, May 18: Alembic Pharma crashes 8.32%, Natco Pharma down 2.48%, Aarti Drugs declines 2.27%
Indian pharmaceutical stocks traded mostly lower on May 18 2026 during the morning session. The BSE Healthcare index declined 0.87% to 46,781.22, in line with the broader market weakness. The…
Alembic Pharmaceuticals passes ANVISA GMP inspection at Karakhadi facility
Alembic Pharmaceuticals has successfully completed the Good Manufacturing Practice (GMP) inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) at its API-III facility in Karakhadi. T...
Alembic Pharmaceuticals Transcript: Q4 25/26
FY 2026 delivered steady growth with 10% revenue and 16% profit increase, despite margin drag from the US branded launch. FY 2027 targets low double-digit growth, margin improvement, and continued R&D investment, with India and international segments expected to accelerate.
Alembic Pharmaceuticals Quarterly report: Q4 2026
Alembic Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 15, 2026.
Alembic Pharmaceuticals Slides: Q4 2026
Alembic Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Alembic Pharmaceuticals reports 29% rise in Q4 net profit for FY26
Alembic Pharmaceuticals Limited has announced a strong financial performance for the fourth quarter of the fiscal year 2026, with a notable increase in both revenue and net profit. The company…
Alembic Pharmaceuticals Q4 Results: Net profit jumps 29% YoY to Rs 202.70 crore, revenue up 4%
Alembic Pharmaceuticals reported its Q4 FY26 results with steady revenue growth and strong improvement in net profit on a year-on-year basis. The company’s revenue from operations stood at ₹1,847.72 c...
Alembic Pharmaceuticals receives USFDA inspection report for Karakhadi facility
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Injectable Facility (F-III) located at Karakhadi. The report was ...
Alembic Pharmaceuticals gets USFDA tentative approval for Darolutamide 300mg — a $3.15 billion prostate cancer market
Alembic Pharmaceuticals Limited has received tentative approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Darolutamide Tablets, 300 mg — a generic equivalen...
Alembic Pharmaceuticals receives USFDA tentative approval for Darolutamide Tablets
Alembic Pharmaceuticals Limited has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets, 300 mg. This app...
Alembic Pharmaceuticals notifies shareholders of unclaimed dividends transfer to IEPF
Alembic Pharmaceuticals has informed its shareholders about the impending transfer of shares to the Investor Education and Protection Fund (IEPF) due to unclaimed dividends for seven consecutive years...
Pharma sector stocks surge today, April 27: Sun Pharma jumps 6.62%, Aarti Drugs up 3.50%, Alembic Pharma rises 2.86%
Indian pharmaceutical stocks broadly advanced on Monday morning, with the Nifty Pharma Index rising 2.4% to 23,131.5. The S&P BSE Healthcare Index climbed 1.47% to 44,259.96, outperforming the broader...
Top Stocks For Trade Today, April 27 – Paytm, RBL Bank, IndusInd Bank, L&T Finance, Alembic Pharma and more
A broad set of companies are in focus today based on corporate announcements, regulatory developments, quarterly earnings, and business updates. Corporate Developments & Business Updates Several compa...
Alembic Pharmaceuticals receives USFDA approval for Fingolimod capsules; targets $145 million market
Alembic Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fingolimod Capsules, 0.5 mg....
Alembic Pharmaceuticals receives USFDA approval for Fingolimod Capsules with market size of US$ 145 million
Alembic Pharmaceuticals Limited has secured final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fingolimod Capsules, 0.5 mg. This approval...
Alembic Pharmaceuticals establishes wholly owned subsidiary in Germany
Alembic Pharmaceuticals has announced the incorporation of a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. This strategic move aims to explore new business opportunities in the Eu...
Alembic Pharmaceuticals establishes new subsidiary in Philippines
Alembic Pharmaceuticals has announced the incorporation of a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The new entity has a share capital of Philippine Pesos 12,000,00...
Pharma sector stocks today, April 20: Panacea Biotech falls 2.23%, Alembic Pharma down 2.20%, Strides Pharma gains 1.43%
Pharmaceutical sector stocks traded mixed in early trade on Monday, April 20, 2026, with most counters under mild pressure. The S&P BSE Healthcare Index declined 0.33% to 43,343.25, while the…
Pharma sector stocks today, April 17: Natco Pharma jumps 3.81%, Alembic Pharma up 2.14%, Strides Pharma rises 1.27%
The S&P BSE Healthcare index opened the session marginally in the green at 43,254.35, up 0.02%, while the broader Sensex traded at 78,084.52, up 0.12%. The Nifty 50 was nearly…
Alembic Pharma receives USFDA approval for Methotrexate injection
Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration for its Methotrexate Injection, strengthening its presence in the regulated US market. The compa...
Alembic Pharma receives USFDA approval for Methotrexate injection; stock trades steady
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Methotrexate Injection USP in both multi-dose and single-dose vial formats, the compa...
Alembic Pharmaceuticals receives USFDA approval for methotrexate injection
Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Methotrexate Injection USP. The approval covers both 50 mg/2…